Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut ...

Sanofi and Regeneron's Dupixent has become the first biologic drug to show activity in prurigo nodularis (PN), raising ... to file for approval of Dupixent (dupilumab) in the new indication ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone for ...

Objective: This study analyzes the occurrence and characteristics of adverse drug reactions (ADRs) of dupilumab in children in a real-world setting. It aims to enhance clinical practice and minimize ...

KYMR outlines plans to advance its immunology candidates. As of Dec. 31, 2024, KYMR had $850 million in cash that should fund its operations into mid-2027.

Currently in Phase 1 testing, KT-621 has demonstrated dupilumab-like activity and very good safety ... esophagitis (EoE), chronic spontaneous urticaria (CSU) and prurigo nodularis (PN), among others.

Currently in Phase 1 testing, KT-621 has demonstrated dupilumab-like activity and ... (EoE), chronic spontaneous urticaria (CSU) and prurigo nodularis (PN), among others. Kymera intends to develop ...

Clinical improvements in pruritus and disease severity were observed following 24 weeks of nemolizumab treatment among adults with moderate to severe prurigo nodularis. Adults with moderate to severe ...